for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Diplomat Pharmacy Inc

DPLO.N

Latest Trade

6.20USD

Change

0.01(+0.16%)

Volume

123,603

Today's Range

6.15

 - 

6.35

52 Week Range

4.17

 - 

17.01

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
6.19
Open
6.16
Volume
123,603
3M AVG Volume
15.61
Today's High
6.35
Today's Low
6.15
52 Week High
17.01
52 Week Low
4.17
Shares Out (MIL)
75.83
Market Cap (MIL)
470.15
Forward P/E
-2.32
Dividend (Yield %)
--

Next Event

Q3 2019 Diplomat Pharmacy Inc Earnings Release

Latest Developments

More

Diplomat Reports Q2 Loss Per Share $2.13

Diplomat Announces Review Of Strategic Alternatives

Diplomat Pharmacy Q1 Loss Per Share $0.19

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Diplomat Pharmacy Inc

Diplomat Pharmacy, Inc. (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company's primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions. The Company provides specialty pharmacy support services to a national network of retailers and independent pharmacy groups, hospitals and health systems. The Company offers various services, such as specialty drug dispensing, retail specialty services, hospital and health system services, and hub services. The Company's patient care system is used to coordinate and track patient adherence and safety.

Industry

Major Drugs

Contact Info

4100 S Saginaw St

+1.888.7204450

https://www.diplomat.is/

Executive Leadership

Brian T. Griffin

Chairman of the Board, Chief Executive Officer

Philip R. Hagerman

Chairman Emeritus

Daniel Paul Davison

Chief Financial Officer, Treasurer

Dave Loschinskey

Chief Operating Officer

David Skomo

Chief Operating Officer - CastiaRx

Key Stats

3.08 mean rating - 12 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

4.4K

2017

4.5K

2018

5.5K

2019(E)

4.9K
EPS (USD)

2016

0.820

2017

0.840

2018

0.720

2019(E)

-2.670
Price To Earnings (TTM)
--
Price To Sales (TTM)
0.09
Price To Book (MRQ)
1.55
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
190.51
LT Debt To Equity (MRQ)
144.93
Return on Investment (TTM)
-47.49
Return on Equity (TTM)
-30.18

Latest News

Latest News

Diplomat says he was told U.S. aid for Ukraine tied to request for probes - Washington Post

The top U.S. diplomat in Ukraine said on Tuesday he was told the United States was withholding aid from Ukraine to try to secure a public commitment for investigations relating to the 2016 U.S. presidential election and a Ukrainian company where former Vice President Joe...

Diplomat Pharmacy pulls forecast, delays results; shares hit record low

Diplomat Pharmacy Inc said on Friday it would withdraw its 2019 forecasts and delay its fourth-quarter and annual results as lower-than-expected performance in its pharmacy benefits management (PBM) business could result in a charge.

Diplomat Pharmacy delays annual results after impairment charge

Diplomat Pharmacy Inc said on Friday it would delay its annual and fourth-quarter results after determining that the company will need to record a charge related to its pharmacy benefits management (PBM) business.

BRIEF-Diplomat Pharmacy Posts Q4 Adj. Earnings Per Share $0.18

* DIPLOMAT ANNOUNCES 4TH QUARTER AND 2017 YEAR END FINANCIAL RESULTS; PROVIDES 2018 GUIDANCE

BRIEF-Diplomat Pharmacy Says Dispensing Advanced Kidney Treatment, CABOMETYX

* DIPLOMAT PHARMACY INC - IS DISPENSING EXELIXIS' LIMITED-DISTRIBUTION TREATMENT CABOMETYX NOW WITH AN EXPANDED INDICATION Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

BRIEF-Diplomat Reaffirms 2017 Guidance And Provides Preliminary 2018 Outlook

* DIPLOMAT PHARMACY INC - JEFF PARK, HAS BEEN APPOINTED INTERIM CHIEF EXECUTIVE OFFICER, EFFECTIVE IMMEDIATELY

BRIEF-Diplomat Reaffirms 2017 Guidance, Provides Preliminary 2018 Outlook

* - EXPECTS 2017 REVENUE TO BE NEAR MIDDLE OF PREVIOUSLY PROVIDED RANGE

BRIEF-Diplomat Completes Acquisition Of LDI Integrated Pharmacy Services

* DIPLOMAT COMPLETES ACQUISITION OF LDI INTEGRATED PHARMACY SERVICES, SECURES NEW CREDIT FACILITIES

BRIEF-Diplomat Adds Chris Luthin As Executive Vice President

* DIPLOMAT ADDS CHRIS LUTHIN AS EXECUTIVE VICE PRESIDENT Source text for Eikon: Further company coverage:

Diplomat Pharmacy plunges as investors fret over rapid PBM push

Shares of Diplomat Pharmacy Inc <DPLO.N> tumbled 20 percent on Thursday after the company acquired a second pharmacy benefit manager in less than a month, sparking concerns it is expanding into a business that is under heightened regulatory scrutiny.

BRIEF-Diplomat to acquire LDI Integrated Pharmacy Services

* Diplomat Pharmacy Inc - will pay LDI $515 million cash and approximately $80 million in diplomat common stock

BRIEF-Diplomat to acquire National Pharmaceutical Services

* Diplomat to acquire National Pharmaceutical Services Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

BRIEF-Diplomat Pharmacy announces 3rd quarter financial results

* Q3 revenue $1.125 billion versus I/B/E/S view $1.16 billion

BRIEF-Diplomat Pharmacy to acquire Pharmaceutical Technologies Inc

* Diplomat Pharmacy - entered agreement to acquire Pharmaceutical Technologies Inc, doing business as National Pharmaceutical Services

BRIEF-Diplomat Pharmacy to dispense newly approved hep C oral drug Mavyret

* Diplomat Pharmacy Inc says is dispensing newly approved Mavyret oral tablets for chronic Hepatitis C virus infection Source text for Eikon: Further company coverage:

BRIEF-Diplomat Pharmacy - ‍now dispensing opioid-overdose antidote naloxone to Michigan residents​

* Diplomat Pharmacy Inc - now dispensing opioid-overdose antidote naloxone to Michigan residents Source text for Eikon: Further company coverage:

BRIEF-Diplomat Pharmacy Q2 adjusted earnings per share $0.25

* Q2 earnings per share view $0.15 -- Thomson Reuters I/B/E/S

BRIEF-Diplomat Pharmacy says Nerlynx tablets for HER2+ breast cancer in the extended adjuvant setting

* Nerlynx™ (neratinib) tablets for HER2+ breast cancer in the extended adjuvant setting

BRIEF-Diplomat Pharmacy begins dispensing prescriptions for RA drug Kevzara

* Diplomat to dispense kevzara® for treatment of rheumatoid arthritis

BRIEF-Diplomat Pharmacy Q1 revenue $1.079 billion

* Q1 earnings per share view $0.15 -- Thomson Reuters I/B/E/S

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up